Transforming Lives Through Research - Spectrum Health · 2016-10-24 · Transforming Lives Through Research Spectrum Health Research Report 2014. 2 Table of Contents Letter from the

1

Transforming Lives Through Research

Spectrum Health Research Report 2014

2

Table of Contents

Letter from the Vice President of Research Page 3Leading the Region in Research Page 4A Collaborative Spirit Page 8Featured Research Initiatives Page 9Research Funding and Administration Page 20Fiscal Year 2014 Grant Awards Page 21Fiscal Year 2014 Publications and Presentations Page 24

3

In this report, we highlight exciting Spectrum Health research focused on cardiovascular, cancer, neurosciences, pediatrics, women’s health and musculoskeletal sciences work. These researchers, who represent the more than 100 physician-scientists throughout Spectrum Health, offer hope and transform lives through their research. We are proud of their efforts.

Research supports our institution’s four key strategies in the following ways:

Drive Exceptional Value – Peer-reviewed, investigator-initiated research that brings novel treatments and/or care to our patients, their families and the community. This research will drive a healing experience that is safe, of high quality and at the forefront of patient care.

Transform the Care Model – An environment where interdisciplinary teams of physicians, other patient care providers and researchers work together to drive patient-centered research, ultimately influencing how best to deliver local, evidence-based care to our patients.

Grow With Purpose – We are committed to supporting and developing areas of research emphasis, as well as providing a means for investigator-initiated research.

Lead New Health Solutions – Through new research initiatives, our physicians will lead the discovery of innovative health solutions.

In the past year, our portfolio expanded beyond clinical research to include basic and translational research initiatives. We opened the Spectrum Health Basic and Translational Research Laboratories to support this important work. For the first time, we received investigator-initiated research funding from the National Institutes of Health, raising the academic stature of our institution.

Academic, protected-time positions now exist for our physicians, and we extended the first appointments for assistant, associate and senior scientist positions. We also created adjunct research positions to encourage association and enhance collaboration with community research institutions, and offered our first adjunct appointments.

We continue to push research forward and promote life sciences education throughout our region through strong inter-institutional commitments and community partnerships. By collaborating with others in medical research, biomedical research and education, we can make an even greater impact on our community and clinical care.

In these and countless other ways, research embodies Spectrum Health’s mission to improve the health of the communities we serve. The momentum of 2014 continues as we focus on transforming lives, one discovery at a time.

Sandra A. Rempel, PhDVice President of Research

4

Leading the Region in Research

Spectrum Health is home to West Michigan’s largest and only fully accredited health system-based clinical research program. More than 90 percent of Grand Rapids- area clinical studies are connected to Spectrum Health.

Fiscal Year 2014 Facts:• $20.7 million portfolio• 863 clinical studies• 116 published articles• More than 100 researchers

At Spectrum Health, our mission is to improve the health of the communities we serve. We understand that future breakthroughs in medical treatments are founded on the clinical, basic and translational research of today.

Clinical ResearchSpectrum Health continues to be a champion of clinical research since launching clinical trials in the late 1970s. Many of those early studies—surfactant for premature infants whose lungs are not fully developed, platinum-based chemotherapy and lasers for treatment of coronary artery disease—are now routinely used.

More than 97 percent of research at Spectrum Health is clinical, of which 81 percent is patient-oriented research. Thousands of patients each year choose to participate in Spectrum Health’s clinical trials. The clinical research is led by cardiovascular,

hematology/oncology, pediatric, clinical neurosciences, orthopedics, women’s health, emergency medicine and many other specialties.

Spectrum Health’s Human Research Protection Program is fully accredited by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), a non-profit accrediting entity that works with organizations involved in clinical research to establish high standards for the protection of participants.

The types of clinical research performed at Spectrum Health include:

Patient-oriented research. Our physician scientists conduct research with human subjects, such as clinical trials, or on material of human origin such as tissues and other specimens. Clinical trials are used to determine whether new biomedical or behavioral interventions are safe and effective, such as drugs, treatments and devices, or new ways of using known drugs, treatments or devices.

Epidemiologic and behavioral studies. Epidemiologic studies investigate factors that determine the presence or absence of diseases and disorders, and their societal and economic impact. Behavioral studies systematically analyze and investigate human behavior through controlled and naturalistic observation, and disciplined scientific experimentation.

Outcomes and health services research. This type of research measures the changes that occur in people’s health and satisfaction due to specific medical and health interventions. It is the study of the delivery and consequences of health care on outcomes from the perspectives of patients, providers and the health care system.

5

Outcomes and Health Services Research 11%

Patient-Oriented Research 81%

Federally Funded – Clinical Research 7%

Industry-Sponsored – Clinical Trials 49%

Epidemiologic and Behavioral Studies 8% Investigator-Initiated – Clinical Research 19%

Consortium-Funded – Clinical Trials 10%

Federally Funded – Clinical Trials 6%

Investigator-Initiated – Clinical Trials 9%

























Types of Clinical Research Performed

Clinical Research by Funding Source

Stephanie Scott, senior research technician

6

The Spectrum Health Basic and Translational Research Laboratories, located in the Cooper’s Landing Building at 1345 Monroe Avenue, opened in August 2013 with more than 9,000 square feet of dedicated research space.

6

7

Basic and Translational ResearchThrough basic research, we aim to understand the biologic basis of disease so that we can design effective therapies and new treatments. Recently, Spectrum Health’s focus has broadened to include translational research—the development of laboratory discoveries into potential diagnostic tools, drugs or medical devices—for use at the bedside.

The following novel clinical initiatives were announced in fiscal year 2014, supported by research at Spectrum Health’s Basic and Translational Research Laboratories. These efforts brought National Institutes of Health Investigator-Initiated Research (R01) funding for basic and translational research to Spectrum Health for the first time, raising the academic stature of our institution.

Helen DeVos Children’s Hospital Pediatric Urology ProgramThe program cares for children with urinary and reproductive tract anomalies. It is complemented by the pediatric urology research laboratory, directed by Kirstan Meldrum, MD, to discover new approaches to repair the damaged kidneys of children.

The Neuroblastoma and Medulloblastoma Translational Research Consortium Headquartered at Helen DeVos Children’s Hospital, the Neuroblastoma and Medulloblastoma Translational Research Consortium is an association of 22 universities and children’s hospitals offering a nationwide network of childhood cancer clinical trials. It is complemented by the neuroblastoma translational research laboratory, directed by Giselle Sholler, MD, to identify new and individualized therapies for children with tumors of the nervous system.

The Adult Bone Marrow Transplant ProgramThe program focuses on transplants for patients with lymphoma, leukemia, multiple myeloma and myelodysplastic syndrome (MDS), performing both autologous and donor transplants. It is complemented by the laboratory of blood and marrow transplantation research, directed by Samer Al-Homsi, MD, to explore new avenues to prevent graft-versus-host disease.

The Brain and Spine Tumor CenterThe center is a partnership between Spectrum Health Medical Group neuroscience experts and the Spectrum Health Cancer Center. It provides advanced and effective brain tumor and spine tumor treatments with individualized care plans. It is complemented by the molecular neuro-oncology laboratory, directed by Sandra Rempel, PhD, to discover novel therapeutic targets for the treatment of brain tumors based on the genetics of a patient’s tumor.

8

A Collaborative Spirit

One-of-a-Kind Community PartnershipsGrand Rapids, Michigan, is home to several institutions for medical research, biomedical research and education of the life sciences. These institutions include Spectrum Health, Van Andel Institute, Michigan State University College of Human Medicine and Grand Valley State University.

The collaborative spirit of Grand Rapids is reflected in the strong inter-institutional commitments to promote research and education. By working together, these institutions promote stronger research programs than any one institute could develop on its own. Examples of Spectrum Health’s collaboration with our community colleagues include the following:• Partnership with Michigan State

University College of Human Medicine in support of collaborative

research programs in orthopaedics, women’s health, neurodegenerative disease and pediatric neurosciences

• Spectrum Health Frederik Meijer Heart & Vascular Institute and the Van Andel Institute partnered to build an inter-institutional program in cardiovascular basic and translational research and clinical trials

• Partnership with Grand Valley State University to support the launch of a new executive MBA program, designed to educate professionals with a focus on health care for Grand Rapids

• Partnership with Michigan State University College of Human Medicine and Grand Valley State University to provide medical and science students with much-needed research fellowships and internships, benefiting both the students and the laboratories they serve

National RecognitionIn addition to investigator-initiated research, Spectrum Health’s research portfolio supports national research ranging from consortia to national tissue-based initiatives.

Headquartered at Spectrum Health, the Cancer Research Consortium of West Michigan (formerly the Grand Rapids Clinical Oncology Program) offers new and unique national cancer clinical trials through a community-based clinical research program. The consortium is funded through a competitive award from the National Cancer Institute.

The Spectrum Health Universal Biorepository Program is dedicated to the collection and storage of patient specimens used for academic and industrial research. The program participated as a tissue and data source site for The Cancer Genome Atlas project, which is a nationwide initiative funded by the National Institutes of Health to map the cancer genome. Involvement in this project is limited, and selected sites must meet strict criteria for inclusion.

8

9

Cardiovascular Research Highlights

Spectrum Health has an established strength in cardiovascular research. Highlights in fiscal year 2014 include the following.

The Frederik Meijer Heart & Vascular Institute The Institute brings together cardiovascular expertise in clinical care, research and education. The institute oversees more than 60 scientists and students in the areas of tissue engineering, myocardial regeneration, stem cell biology, end-stage heart failure and transplant immunology. Annually, about 50 active cardiovascular clinical trials have Institute physicians as principal investigators.

Minimally Invasive Cardiac Surgery Clinical TrialPhysicians in the Spectrum Health Frederik Meijer Heart & Vascular Institute have participated with other institutions on a clinical trial to evaluate an alternative to open-heart surgery for patients with severe aortic stenosis. The Medtronic CoreValve® System is designed to provide a minimally invasive, transcatheter treatment option for patients with symptomatic, severe aortic stenosis who are at high risk or who are ineligible for open-heart surgery.

Discover Magazine’s “Top 100 Stories of 2013”Discover Magazine selected original cardiovascular research conducted at Spectrum Health as one of the “Top 100 Stories of 2013.” Spectrum Health cardiologist Ryan Madder, MD, used near-infrared spectroscopy to identify the characteristic makeup, or signature, of arterial plaque. Arterial plaque blocks arteries and causes heart attacks. The study was ranked 53rd among the top science stories of 2013.Photo above: Angiogram and corresponding chemogram of a patient with an ST-segment elevation myocardial infarction. Arrow indicates a large lipid core plaque.

10

Getting to the heart of it: New device seals area to prevent leaks

International clinical study evaluates safety and efficacy of aneurysm sealing system for endovascular repair

The aorta is the body’s main artery, carrying blood from the heart to the rest of the body. An AAA is an enlarged and weakened section, or “ballooning” of the aorta, that is prone to rupture and often results in death. According to the Centers for Disease Control and Prevention, approximately 13,000 Americans die each year from thoracic and abdominal aortic aneurysms. Most of the deaths result from rupture or dissection, a kind of splitting of the aorta.

A stent-graft can be used to repair an AAA. A stent-graft is a long, cylinder-like tube made of a thin metal stent frame covered with a graft material such as polyester. The stent helps to hold the graft in place. The stent-graft is inserted into the aorta and placed at the site. Once in place, the stent-graft is expanded, attaching to the wall of the aorta and supporting it. The aneurysm eventually shrinks down onto the stent. Most times two or more stent pieces are combined to repair the aneurysm.

Dr. Cuff explained two common complications with this procedure. One is blood from small vessels leaking

back into the aneurysm sac, the space created between the stent and the damaged aorta. The other complication is shifting of the stent-graft, which can cause the pieces to separate. This can cause the stent-graft to leak, requiring a surgical repair. These complications can occur in up to 20 percent of cases and require additional surgeries to repair.

“This Nellix system includes an additional step in performing a minimally invasive AAA repair,” said Dr. Cuff. “Once the stents are in place, special endobags surrounding the stents are filled with a resin-like polymer material that fills the remaining aneurysm sac to protect the aorta while excluding and sealing the aneurysm from blood flow. By sealing the aneurysm sac, we hope to learn if this will significantly reduce these complication rates.”

Enrollment under an extended investigation phase is anticipated to begin shortly, and will continue during the pivotal trial follow-up period and premarket access reparation/review process.

Spectrum Health is participating in an international clinical trial for a new investigational device designed for the repair of some abdominal aortic aneurysms (AAA).

The EVAS FORWARD trial, sponsored by Endologix, Inc., evaluates the safety and efficacy of the Nellix™ EndoVascular Aneurysm Sealing System (EVAS). The device is not commercially available in the United States, and is available only at selected clinical study sites for investigational use. It is only for infrarenal AAAs, which occur below the renal arteries, the blood vessels that lead to the kidneys.

The trial is designed to determine if a new stent graft procedure that seals the AAA repair in a polymer will result in reduced leaks and surgical repairs. The trial enrolled 179 patients at 29 centers in the U.S. and Europe. Spectrum Health physicians performed the Nellix procedure on 19 patients.

Spectrum Health Medical Group vascular surgeon Robert Cuff, MD, leads the trial at the Spectrum Health Fred and Lena Meijer Heart Center.

11

Before and after pictures of a recent case. Note the

large AAA with bilateral iliac artery aneurysms and large secondary (lumbar vessels)

still patent on the aneurysm. After being treated with

the Nellix device, there is complete sealing and

exclusion of the aneurysm sac and iliac aneurysm with

no backfilling from the lumbar vessels.

Robert Cuff, MD

12

Using a cancer’s genetic profile to guide treatment

The landscape of cancer care is evolving due to the increased availability of information about biomarkers (alterations in DNA or protein expression) present in a patient’s tumor, which make each individual’s cancer unique.1,2 New biomarkers, drugs and clinical trials are discovered on a weekly basis. Biomarker-targeted therapy for a patient’s specific cancer represents the new era of cancer treatment.

Personalized medicine is defined as an “emerging practice of medicine that uses an individual’s genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease. Knowledge of a patient’s genetic profile can help doctors select the proper medication or therapy and administer it using the proper dose or regimen” (ghr.nlm.nih.gov/).

Next-generation sequencing (NGS) is a technology that may be used to identify certain biomarkers in a patient’s cancer tumor. This can now be performed in real time, with the potential to impact

Multidisciplinary teams explore an infrastructure for personalized cancer care

therapeutic decisions in patients with complex, advanced or recurring cancer. Early efforts at major academic centers suggest personalized cancer care can be delivered; however, substantial institutional resources are required to get started.2,3,4 With the availability of biomarker testing in referral laboratories such as Foundation Medicine and Caris Life Sciences®, clinicians in a wider number of centers can pursue such testing by sending it outside their centers.5,6

Another approach is to perform biomarker testing in-house through the center’s Clinical Laboratory Improvement Amendments (CLIA)-approved Spectrum Health Advanced Technology Laboratory. This offers the benefits of quicker turnaround times and confirmation of test results with standard sequencing technologies, all at a reduced cost compared to biomarker testing available at referral laboratories.

Although the cost and availability of biomarker testing are becoming less

problematic, the integration of such testing into clinical care remains a challenge and has largely been left up to the treating physician. Several questions remain regarding the feasibility of providing personalized cancer care using biomarker results in non-university cancer centers where the majority of patients receive their care.7–10 Once biomarker results are obtained, major academic centers have convened molecular tumor boards that include broad participation of clinical experts, translational scientists and others in their initial efforts in this space.

Brian Lane, MD, PhD, chief of urology, Spectrum Health Medical Group and Spectrum Health Betz Family Endowed Chair for Cancer Research, wanted to determine if a regional Center for Personalized Cancer Care could employ the same options for patients.

A pilot trial exploring the feasibility of convening an institutional multispecialty tumor sequencing advisory board (TSAB) of professionals to evaluate

Spectrum Health Advanced Technology Laboratory remains the only CLIA-approved laboratory in West Michigan performing clinical biomarker testing on a next-generation sequencing platform.

13

biomarker results at Spectrum Health was recently completed. During the course of the 15-patient trial, the team outlined and expanded the roles, functions and interaction of the various stakeholders, forming a cohesive and multidisciplinary board averaging 16 or more members per meeting.

The pilot study involved analysis of cancer tumor tissue from 15 patients using a biomarker test (Ion Torrent AmpliSeq Cancer Hotspot Panel v2) performed in-house by the CLIA-approved Spectrum Health Advanced Technology Laboratory. Cancer tumor samples were obtained from Spectrum Health’s biorepository and analyzed at 2,800 frequently mutated sites in 50

genes. The primary outcome of interest was the proportion of multidisciplinary TSAB discussions regarding biomarker results and corresponding therapies occurring in a clinically meaningful time frame. Secondary outcomes included TSAB function and processes, biomarker test turnaround time, and proportion of reports with biomarker results associated with a targeted therapy. The study results will be submitted for publication in early 2015.

“From this pilot study, we developed the essential components of a Center for Personalized Cancer Care, which can provide decision support for clinicians utilizing NGS [biomarker testing] in this era of genomic medicine,” said

Dr. Lane. “Clinically significant mutations were identified in 73 percent of patients, identifying potential druggable targets in patients who may also be eligible for innovative clinical trials.”

After proof of feasibility, the Hotspot Panel is now offered as a clinically available test at Spectrum Health Advanced Technology Laboratory, with a turnaround time of 10 to 14 days on average. Spectrum Health Advanced Technology Laboratory remains the only CLIA-approved laboratory in West Michigan performing clinical biomarker testing on a next-generation sequencing platform.

“Our laboratory continues to work with physicians to develop additional clinically useful biomarker panels in order to provide affordable, state-of-the-art, personalized cancer care for patients in this quickly progressing field,” said Kim Collison MSA, MT (ASCP), Spectrum Health Advanced Technology Laboratory manager. “In addition to the Hotspot Panel, we also offer the National Comprehensive Cancer Network (NCCN)-recommended extended mutation testing (NRAS and KRAS). This testing provides information to assist the physician in the determination of effective drug therapy for metastatic colon cancer.”

Other biomarker testing currently in development includes a non-small cell lung cancer panel and a hematology oncology panel.

1. Garraway et al., “Precision oncology: an overview,” J Clin Oncol 31 (2013): 1803-1805.

2. Meric-Bernstam et al., “Building a personalized medicine infrastructure at a major cancer center,” J Clin Oncol 31 (2013): 1849-1857.

3. Roychowdhury et al.,“Personalized oncology through integrative high-throughput sequencing: a pilot study,” Sci Transl Med 3 (2011): 111-121.

4. Tsimberidou et al., “Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative,” Clin Cancer Res 18 (2012): 6373-6383.

5. Sweeney et al., “Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial,” (2014) Chicago, IL, pp. 5s.

6. Overton et al., “Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting,” J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32 (2014): 11028.

7. Alzu’bi et al., “Personal genomic information management and personalized medicine: challenges, current solutions, and roles of HIM professionals,” Perspect Health Inf Manag 11 (2014): 1c.

8. Overton et al., “Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting,” J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32 (2014): 11028.

9. Garralda et al., “Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment,” Clin Cancer Res 20 (2014): 2476-2484.

10. Gray et al., “Physicians’ attitudes about multiplex tumor genomic testing,” J Clin Oncol 32 (2014): 1317-1323.

References

Brian Lane, MD

14

Clearer picture of the brain helps pinpoint seizures

The gold standard for identifying the source of epileptic seizures is to place electrodes in specific areas of the brain to map the location of the seizure onset and its impact. Brain mapping is the process of directly stimulating the brain through the same implanted electrodes to determine areas of the brain that cannot be removed, because their loss would result in permanent dysfunction. Often once the source of the disturbance is identified, that section of the brain is surgically removed if possible.

Although these methods are considered the most accurate way to localize seizures and map brain function, many are attempting to design a noninvasive technological process that can complete these tasks without actually having to

Neuroimaging opens door to more precise epilepsy treatment

directly place electrodes on the brain surface. Functional MRI (fMRI) is the most frequently utilized technology to map brain function noninvasively. But to determine its true accuracy, this data in many cases still has to be directly compared to direct electrical recordings.

In recent years, it has become clear that there are networks in the brain that may be causing seizures rather than a single, discrete location. With the use of functional MRI technology (fMRI), we are able to see these networks in action and track how signals are traveling in the brain. Now it is possible to combine these two techniques for a comprehensive view of epileptic focal points. This dual approach provides a non-invasive, big picture perspective from the fMRI along with results from small electrodes implanted for brain mapping. Spectrum

Health is one of the few centers in the country that is mapping networks in the brain using both electrical and MRI approaches to more clearly pinpoint the location of seizures.

Spectrum Health Medical Group neurosurgeon Kost Elisevich, MD, PhD, and epileptologist Brien Smith, MD, along with researchers from Henry Ford Hospital, Wayne State University, Michigan State University and Grand Valley State University, are collaborating on studies in this area. They are evaluating the broader perspective that can be gained by combining fMRI with the traditional electrode approach of localizing the source of seizures.

Two clinical trials are under way, with patients enrolled in both. One study is using a special imaging protocol to segment, quantify and characterize

15

Spectrum Health is one of the few centers in the country that is mapping networks in the brain using both electrical and MRI approaches to more clearly pinpoint the location of seizures.

brain structures on both magnetic resonance imaging (MRI) and Single Photon Emission Computed Tomography (SPECT) and determine how these attributes may relate to the underlying source of epileptic tissue in the temporal lobe. As patients are acquired in this database, the findings from imaging analysis will be compared to the clinical diagnosis, surgical intervention and outcomes. The ultimate goal of this study is to develop methods and systems that facilitate and improve diagnosis, treatment planning, treatment evaluation and prognosis while reducing risk and cost.

The second study attempts to undertake a comprehensive picture of focal epilepsy (seizures coming from one specific area of the brain) using sophisticated imaging and intracranial

electrographic recording (measured electrical brain activity with electrodes implanted into the brain or placed on the surface). This study will attempt to analyze multiple characteristics about epileptic tissue, including electrical characteristics, altered cellular makeup, brain morphology, extent of the abnormal network and consequences of inflammatory changes.

Further understanding of the anatomical, electrical, cellular, genetic and inflammatory characteristics that alter brain networks and result in epileptic circuits may allow us to design interventions that modify this pathological process.

Brien Smith, MD, and Kost Elisevich, MD

16

Just as every child is different, every tumor can be different

In 2003, the first human genome was sequenced after 13 years of work. Today we can sequence a patient’s DNA and their tumor’s DNA in less than a month, opening new possibilities and informing new ways of treating children with cancer. We can personalize treatment by understanding what genes make a tumor grow and divide, and what genes make a tumor resistant to therapy. This makes it possible to determine specific treatment for each child based on their genetic information.

Giselle Sholler, MD, Haworth Endowed Director of Pediatric Oncology Innovative Therapeutics at Helen DeVos Children’s Hospital, is leading the Pediatric Oncology Research Program. This includes our Molecularly Guided Therapy Clinical Trial, Signatures Program and Early Phase Clinical Trials Program. The goal of the personalized medicine studies is to profile the genetic makeup of all tumors for each child diagnosed with any type of cancer at Spectrum Health Helen DeVos Children’s Hospital.

One example of this personalized approach is Tristin’s treatment on our Molecular Guided Therapy Trial

Clinical studies explore a personalized approach to treating childhood cancer

funded through our Dell Grant. Now an 18-year-old boy, he was diagnosed with Stage 4 neuroblastoma at 13 years of age. He received an initial high dose of chemotherapy and his tumor remained. He then traveled from his home in Tennessee to a medical center in New York City, where he was treated with more high-dose chemotherapy for three years.

Tristin came to Helen DeVos Children’s Hospital in February 2013. He was one of the first patients we were able to treat in this completely new way of caring for children using personalized medicine. Following his tumor profile and adjusting his treatment as it changes has brought hope, allowing Tristin to graduate from high school and even start college.

The Signatures Program involves the collection of normal and malignant patient tissues to determine the molecular makeup of these tissues and correlate with clinical data. This will be used to identify diagnostic markers that could be used to detect disease progression and response to therapy, and identify optimal molecularly informed treatment options (both novel targets and targets of existing drugs). These

new agents will be tested in laboratory models of patients and development of phase I clinical trials.

“Identifying an important gene in neuroblastoma targeted by a drug called DFMO, we created the first clinical trial to target cancer stem cells and prevent children from relapsing,” said Dr. Sholler. “This trial is showing great promise, and children are staying in remission. Our goal in this study is to increase the rate of children staying in remission from 60 to 80 percent.”

Tissue samples are collected from new and relapsed childhood cancer patients at Helen DeVos Children’s Hospital and at 22 other children’s hospitals within the Spectrum Health-led national consortium, the Neuroblastoma Medulloblastoma Translational Research Consortium. Every one of these samples will be analyzed using the latest molecular profiling technologies and computational techniques to identify molecular biomarkers and targeted drug interventions, which can be used by doctors to look for the best treatment options for their patients.

Giselle Sholler, MD

17

Blood transfusions could harm children with traumatic injuryStudy finds pediatric blood conservation results in better outcomes

The pediatric critical care team at Spectrum Health Helen DeVos Children’s Hospital has been focused on blood management during the past 16 years and is recognized nationally for optimizing patient outcomes by minimizing blood product utilization.

One study published in 2014 examined the outcomes of transfused trauma patients. RBC Transfusions in Children Requiring Intensive Care Admission After Traumatic Injury was published in the June 2014 edition of Pediatric Critical Care Medicine.

Trauma is a frequent occurrence in the pediatric population. The Centers for Disease Control and Prevention reports that trauma is a leading cause of death for individuals ages 1 to 44. It is estimated that 10 – 15 percent of children hospitalized after trauma have life-threatening injuries that demand an expedient and systematic approach to their care.1 Packed red blood cell (PRBC) transfusions to critically injured patients are considered life-saving therapy, especially when administered

This pediatric study, as well as other studies in adults, adds to the body of evidence that PRBC transfusions, particularly of increased storage age, may be harmful to patients after traumatic injury.

in response to hemodynamic instability after hemorrhage. However, studies show that after significant injuries, the patient may deteriorate into a generalized body inflammation and compromised body immunity.2, 3 In these situations, transfusions may worsen the patient’s condition.4

“Our analysis was intended to define the characteristics of transfused pediatric trauma patients compared with the non-transfused patients and to evaluate the frequency, timing, quantity and storage age of PRBC transfusions received during their PICU stays,” said Nabil Hassan, MD, lead author of the study and medical director of pediatric blood management at Helen DeVos Children’s Hospital. “We also examined the relationship of these factors to clinical course and eventual outcomes to improve the quality of care offered to trauma patients.”

In this retrospective review, PRBC transfusions of pediatric trauma patients were associated with worse clinical outcomes independent of the severity of injury. Frequency and volume of transfusions, as well as blood older than 28 days, seem to be contributing factors to these outcomes. This pediatric study, as well as other studies in adults,

adds to the body of evidence that PRBC transfusions, particularly of increased storage age, may be harmful to patients after traumatic injury.

“Given this evidence, it may be appropriate to reexamine indications for transfusions, and consider implementing blood conservation strategies to minimize transfusion needs,” said Dr. Hassan.

Additional authors include James M. DeCou, MD; Dianne Reischman, PhD; Todd A. Nickoles, RN, BSN; Emily Gleason, RN, BSN; Diana L. Ropele, RN, MSN; Dominic Sanfilippo, MD; Alan T. Davis, PhD; David Alters, MD; Surender Rajasekaran, MD, MPH.

Helen DeVos Children’s Hospital physicians have published several studies, with more under way, examining the results of blood management in critically ill children, premature newborns, patients with cancer and blood disorders, and those undergoing surgery. Those who have collaborated on blood management efforts and research include Brian Boville, MD, Philip Nowicki, MD, John Kampinen, MD, Jeffery Cassidy, MD, Deb Cloney, MD, Harold Conrad, MD, Deanna Mitchell, MD, and Beth Kurt, MD.

1. Falcone et al., “A multicenter prospective analysis of pediatric trauma activation criteria routinely used in addition to the six criteria of the American College of Surgeons,” J Trauma Acute Care Surg 73 (2012): 377-384.

2. Asehnoune et al., “Innate immune dysfunction in trauma patients: From pathophysiology to treatment,” Anesthesiology 117 (2012):411–416.

3. Gentile et al., “Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care,” J Trauma Acute Care Surg 72 (2012):1491–1501.

4. Hendrickson et al, “Noninfectious serious hazards of transfusion,” Anesth Analg 108 (2009):759–769.

References

17

Nabil Hassan, MD

18

Options for treating rare condition of the placenta

A rare cancer of the placenta, gestational trophoblastic neoplasia (GTN), affects about one in 1,000 pregnant women in the U.S. each year.1 While rare, this disease can become malignant and fatal. Julian Schink, MD, Spectrum Health Medical Group chief of women’s health, is principal investigator of an international phase III randomized trial comparing two chemotherapy drugs used to treat the disease.

This study (Gynecologic Oncology Group Study 275) tests the hypothesis that treatment with multi-day methotrexate is inferior to treatment with a regimen known as pulse actinomycin-D, administered once every two weeks, in low-risk gestational trophoblastic disease.

The abnormal growth in the placenta occurs in women of reproductive age and can be benign or malignant. The disease can be fatal but is curable if diagnosed early. The cure rate approaches 100 percent and fertility preservation is usually possible with individualized care based on careful staging and multidisciplinary team planning.2,3,4

In the U.S., pregnant women commonly have ultrasounds, so this condition is

Investigating chemotherapy in the treatment of gestational trophoblastic disease

Our goal is to identify the treatment that is the most convenient and best tolerated by patients. This disease affects young women in the prime of their lives and can be very disruptive to them and their families.

often diagnosed early. Other cultures, particularly in the developing world, do not use ultrasound as widely, and therefore pregnant women in those countries are often diagnosed with widely metastatic disease.

The condition is so rare that it needs to be studied worldwide to attract enough patients. This National Cancer Institute-funded study currently has 29 patients enrolled. The goal is to accrue 381 patients.

This trial builds on a previous international study of Dr. Schink’s (Gynecologic Oncology Group Study 242), which determined that second curettage (surgical removal of uterine tissue) is a safe, simple alternative to immediate chemotherapy for patients with newly diagnosed, non-metastatic, low-risk GTN.

That study showed that second curettage could be safely offered to

patients regardless of hCG (human chorionic gonadotropin hormone) level and the amount of intra-uterine disease.5 Immediate chemotherapy is still preferred and more effective for patients with a WHO (World Health Organization) risk score of 5 or 6 and for patients at the extremes of reproductive life, specifically under 19 and over 39 years of age. In this study, 46.8 percent of patients derived significant benefit from immediate second curettage and avoided chemotherapy.

“We know that surgical treatment is effective, and now we are investigating chemotherapy drugs to determine which offers the most promise for women with GTN,” said Dr. Schink. “Our goal is to identify the treatment that is the most convenient and best tolerated by patients. This disease affects young women in the prime of their lives and can be very disruptive.”

1. American Cancer Society (www.cancer.org)

2. Seckl et al., “Gestational trophoblastic disease,” Lancet, Vol. 376, No. 9742 (2010): 717-29.

3. Lurain, “Advances in management of high-risk gestational trophoblastic tumors,” J Reprod Med, Vol. 47, No. 6 (2002):451-459.

4. Seckl et al., “Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Ann Oncol, Vol. 24, Suppl 6 (2013): vi39-50.

5. Reade et al., “Treatment of low-risk gestational trophoblastic neoplasia: a probabilistic decision analysis model,” Gynecol Oncol, Vol. 130, No. 1 (2013):e27-28.

References

Julian Schink, MD

19

New hope for people suffering from chronic bone infections

Evaluating the safety and efficacy of new bone graft substitute for musculoskeletal repair

1. Oxford Bone Infection Conference. April 3, 4, 2014, Oxford, England.

2. Roberts, et al., “Size and composition of synthetic calcium sulfate beads influence dissolution and elution rates in vitro,” J Biomed Mater Res B Appl Biomater, Vol. 102, No. 4 (2014):667-73, PMID: 24155136.

3. McConoughey et al., “Comparing PMMA and calcium sulfate as carriers for the local delivery of antibiotics to infected surgical sites,” J Biomed Mater Res B Appl Biomater (2014): PMID: 25142105.

4. Bonesupport. (2014, April 15). First Cerament™|G Study With Local Gentamicin Elution Shows Safe Bone Healing With Effective New Bone Ingrowth in Osteomyelitis Patients. In PR Newswire.

5. McNally et al., “A prospective evaluation of Cerament™ G bone void filler with gentamicin in the treatment of chronic osteomyelitis with cavitary defects,” Paper No. 4, Oxford Bone Infection Conference, April 4, 2014, Oxford, England.

References

Osteomyelitis or bone infection is a major patient problem where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries and an increasing resistance to antibiotics contribute to this growing condition. Current treatment options include the use of a product, such as Cerament™ , a bone void filler used to remodel the bone.

This treatment is combined with prolonged systemic antibiotic therapy. Studies have been undertaken to determine whether antibiotic treatment is more efficacious when locally administered. Initial investigations show remarkable outcome when the antibiotic is locally administered at the time of applying the cement (Fig. 1). However, local administration of the antibiotic can be very difficult, and new devices or methodologies are needed.

Jason Calhoun, MD, chief of musculoskeletal sciences, Spectrum Health Medical Group, has more than 170 peer review publications, 57 chapters and three books mainly on musculoskeletal infection. Dr. Calhoun

was The Cierny Mader International Visiting Professor at the Oxford Bone Infection Conference on April 3, 2014,1 where he presented his research2,3 regarding bone infection treated with antibiotic orthopaedic implants.

While at this conference, Dr. Calhoun first heard Dr. Martin McNally, lead surgeon of the bone infection unit at the Nuffield Orthopaedic Centre in Oxford, United Kingdom, present on a clinical trial of 41 patients with osteomyelitis who were treated with a new product, Cerament™|G, which is the bone void filler combined with the antibiotic gentamicin. The study showed no recurrence of infection, no late wound leakage, no toxicity and no renal complications, with more than 75 percent of patients having complete bone remodeling at six months.4

In a news release about the UK study results, Dr. McNally stated: “Local antibiotic management of osteomyelitis provides a much-needed treatment option for people who suffer from chronic bone infections. We are pleased by early results and are optimistic that CERAMENT™|G offers the potential to improve health outcomes, lower

Left: the tibia canal from a recent case, which has been debrided of a long-standing bone infection in a 29-year-old man and has been filled with the CerementTM bone cement, and local administration of antibiotics. The infection in the canal has been completely replaced with the cement without antibiotic, which is remodeling to normal bone. The patient is without pain, purulent drainage, infection and antibiotics for the first time in 10 years.

healthcare costs and deliver a higher quality of life for patients suffering from this devastating disease.”5

“I have been treating bone infections for many years with the implanting antibiotic devices to treat bone infection and had never seen such a remarkable outcome,” Calhoun said.

Calhoun has approached the company to bring its device to the U.S. and is one of three leading U.S. orthopaedic surgeons developing an international clinical trial. He was part of a group that convened in Washington, D.C., to discuss developing a multimillion-dollar grant to study this treatment in the U.S., with Spectrum Health as one of the three supervisory sites.

Jason Calhoun, MD

20

Research Administration and Funding

Spectrum Health’s Office of Sponsored Programs in the Offices of Research Administration partners with physicians, clinicians, researchers, employees and administrators to develop competitive funding proposals and manage sponsored awards. The office is the central coordination point for all sponsored programs, including government-funded and industry-sponsored grants, contracts and subawards. The office also partners with the Spectrum Health Foundation in the development of internal grants and privately sponsored research grants.

In fiscal year 2014, 105 proposals were submitted, a 13 percent increase over proposals submitted in fiscal year 2013. The office administered 166 awards for total funding of $20.7 million from state and federal government, private sponsors and philanthropic grants in fiscal year 2014. This represents a 65 percent increase over awards managed in fiscal year 2013.

Spectrum Health Office of Sponsored Programs is administering a portfolio that is gradually increasing in federal and state awards, despite the decreasing federal and state funds available to support research. This past year, research was significantly supported by increases in private Foundation and philanthropic support.

In fiscal year 2014, $20.7 million in awards were administered.

Substance Abuse & Mental Health Services Admin. 1.4% Administration for Children and Families 2.8% Agency for Healthcare Research and Quality 4.2% Centers for Disease Control and Prevention 11.3% Centers for Medicare & Medicaid Services 7.0% Department of Defense 2.8% Department of Homeland Security 2.8% Food and Drug Administration 1.4% Health Resources & Services Administration 19.7% National Institutes of Health 46.5%

$12

$10

$8

$6

$4

$2

$02012

Federal

State

External Private/FoundationSpectrum Health Foundation

Fiscal Year

Aw

ard

Tota

ls in

Mill

ions

2013 2014

Substance Abuse & Mental Health Services Admin. 1.4% Administration for Children and Families 2.8% Agency for Healthcare Research and Quality 4.2% Centers for Disease Control and Prevention 11.3% Centers for Medicare & Medicaid Services 7.0% Department of Defense 2.8% Department of Homeland Security 2.8% Food and Drug Administration 1.4% Health Resources & Services Administration 19.7% National Institutes of Health 46.5%

$12

$10

$8

$6

$4

$2

$02012

Federal

State

External Private/FoundationSpectrum Health Foundation

Fiscal Year

Aw

ard

Tota

ls in

Mill

ions

2013 2014

Fiscal 2014 Federal Award Funding (% of funding by organization)

Total Awards Managed per Fiscal Year by Funding Type

20

21

Grants

In fiscal year 2014, $20.7 million in awards were administered.

CANCER RESEARCH

Adult Brain TumorPrincipal Investigator: Rempel, Sandra, PhDProject Title: HSP27: A Modulator and Therapeutic Target of SPARC-Induced Glioma InvasionSponsor: National Institutes of HealthAward Total: $774,853Department: Spectrum Health Brain Tumor Research LabAward Period: 1/4/2011 – 12/31/2015

Adult and Pediatric BMT Principal Investigator: Abdel-Mageed, Aly S., MDProject Title: A Multi-Center Study of Hematopoietic Stem Cell Donor Safety and Quality of Life (Subcontract)Sponsor: National Institutes of Health (Subaward) Award Total: N/A (Per-Patient Reimbursement)Department: Department of Pediatric Bone Marrow TransplantAward Period: 10/1/2009 – open

Principal Investigator: Abdel-Mageed, Aly S., MDProject Title: Collection of Blood Samples From Adult TBI Patients for Sequential Radiation Exposure Analysis (Subcontract)Sponsor: U.S. Biomedical Advanced Research and Development Authority (BARDA) (Subaward)Award Total: $48,906Department: Department of Pediatric Bone Marrow TransplantAward Period: 4/1/2014 – 1/17/2015

Adult and Pediatric Orthopaedic OncologyPrincipal Investigator: Foley, Jessica, MDProject Title: Targeting Chemo-Resistant Subpopulations in Human Osteosarcoma: Development and Implementation of a Novel Therapeutic StrategySponsor: Hyundai Hope On WheelsAward Total: $75,000Department: Helen DeVos Children’s Hospital Department of Pediatric Hematology and Oncology, and Spectrum Health Department of Orthopaedic OncologyAward Period: 8/29/2013 – 4/30/2015

Principal Investigator: Steensma, Matthew, MDProject Title: The Identification of Novel Mutations in Outlier PatientsSponsor: Van Andel Research InstituteAward Total: $1,250Department: Spectrum Health Department of Orthopaedic OncologyAward Period: 2/5/2013 – 2/4/2018

Adult and Pediatric Urologic OncologyPrincipal Investigator: Kahnoski, Richard, MDProject Title: Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) (Subcontract)Sponsor: U.S. Department of Defense (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Spectrum Health Department of UrologyAward Period: 7/1/2012 – 9/30/2015

Biobank and LaboratoryPrincipal Investigator: Cottingham, Sandra, MD, PhDProject Title: The Cancer Genome Atlas (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $101,500Department: Spectrum Health Laboratory and Universal BiorepositoryAward Period: 12/9/2013 – 12/31/2014

Principal Investigator: Cottingham, Sandra, MD, PhDProject Title: The Cancer Proteomics Tumor-Analysis Consortium (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $191,142Department: Spectrum Health Laboratory and Universal BiorepositoryAward Period: 5/1/2014 – 12/31/2015

Colorectal CancerPrincipal Investigator: Hoedema, Rebecca, MDProject Title: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection vs. Open Resection for Rectal Cancer (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Spectrum Health Department of Colon and Rectal SurgeryAward Period: 1/15/2009 – open

General OncologyPrincipal Investigator: Dougherty, Mary, MSN, RN, AOCNSProject Title: Determining Severity, Interference and Number of Days of Symptoms From Side Effects in Cancer Patients Prescribed Oral Chemotherapy Agents, How Comorbid Conditions May Influence (Subcontract)Sponsor: Walther Cancer Foundation Behavioral Cooperative Oncology Group (BCOG) (Subaward)Award Total: $1,650Department: Department of Oncology and Medical-Surgical Nursing AdministrationAward Period: 5/1/2012 – 10/31/2013

22

Principal Investigator: Padula, Gilbert, MDProject Title: Grand Rapids Clinical Oncology Program (GRCOP)Sponsor: National Cancer InstituteAward Total: $1,637,557Department: Grand Rapids Clinical Oncology Program (GRCOP)Award Period: 6/1/2013 – 7/31/2014

Head and Neck CancerPrincipal Investigator: Padula, Gilbert, MDProject Title: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer (Subcontract)Sponsor: National Cancer Institute (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Grand Rapids Clinical Oncology Program (GRCOP)Award Period: 4/1/2013 – 3/31/2015

LungPrincipal Investigator: Patzelt, Lawrence, MDProject Title: Managing Fatigue Using Virtual Reality for Postoperative Lung Cancer Patients (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $47,701Department: Department of CardiologyAward Period: 9/1/2012 – 8/31/2014

Pediatric OncologyPrincipal Investigator: Dickens, David, MDProject Title: Children’s Oncology Group (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Hematology and OncologyAward Period: 4/13/2012 – open

Principal Investigator: Dickens, David, MDProject Title: Children’s Oncology Group (Subcontract)Sponsor: St. Baldrick’s Foundation (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Hematology and OncologyAward Period: 4/26/2012 – open

Principal Investigator: Rajasekaran, Surender, MDProject Title: A Phase III Trial of Calfactant for Acute Lung Injury (ALI) in Pediatric Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Patients (Subcontract)Sponsor: U.S. Food and Drug Administration (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric Intensive CareAward Period: 9/15/2011 – 9/14/2013

Principal Investigator: Sholler, Giselle, MDProject Title: Dell Powering the Possible ProgramSponsor: Dell and Translational Genomics Research InstituteAward Total: $1,932,155 and $1,540,512Department: Helen DeVos Children’s Hospital Department of Hematology and OncologyAward Period: 11/1/2012 – 10/31/2013 and 11/1/2013 – 6/30/2015

Principal Investigator: Sholler, Giselle, MDProject Title: Marrow-Derived Antibody Library for Treatment of NeuroblastomaSponsor: U.S. Department of DefenseAward Total: $60,141Department: Helen DeVos Children’s Hospital Department of Hematology and OncologyAward Period: 9/1/2012 – 9/30/2015

CARDIOVASCULAR RESEARCH

CardiovascularPrincipal Investigator: Wohns, David, MDProject Title: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Department of Cardiovascular Services/West Michigan HeartAward Period: 8/17/2012 – open

Interventional CardiologyPrincipal Investigator: McNamara, Richard, MDProject Title: Risk Stratification in Older Persons with Acute Myocardial Infarction SILVER-AMI (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Department of CardiologyAward Period: 8/18/2012 – 5/31/2015

Vascular SurgeryPrincipal Investigator: Mansour, MA, MDProject Title: Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Department of Surgical SpecialtiesAward Period: 2/26/2008 – 12/31/2016

CRITICAL CARE RESEARCH

Pulmonary Critical CarePrincipal Investigator: Fitch, Stephen, MDProject Title: Practice Pattern Variation in Discontinuing Mechanical Ventilation in Critically Ill Adults: An International Prospective Observational Study (Subcontract)Sponsor: St. Michael’s Hospital (Toronto, ON, Canada) Total: $1,500 (Subaward)Department: Pulmonary Department Award Period: 12/1/2013 – open

EMERGENCY MEDICINE RESEARCHPrincipal Investigator: Jones, Jeffrey, MDProject Title: Persistent Pain and Associated Physical Function Decline Among Elderly Individuals (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Spectrum Health Emergency DepartmentAward Period: 6/5/2013 – 5/31/2015

23

Principal Investigator: Oostema, Adam, MDProject Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $36,500Department: Spectrum Health Emergency DepartmentAward Period: 9/1/2013 – 8/31/2014

NEONATAL RESEARCHPrincipal Investigator: Pastyrnak, Steven, PhDProject Title: Neurobehavioral and Medical Effects of Single-Family Room Design for the Care of High-Risk Neonates: A Randomized, Controlled Study Sponsor: The Gerber FoundationAward Total: $196,630Department: Helen DeVos Children’s Hospital Department of PsychologyAward Period: 11/18/2010 – 8/31/2015

Principal Investigator: Pastyrnak, Steven, PhDProject Title: Neonatal Biomarkers in Extremely Preterm Babies Predict Childhood Brain Disorders (ELGAN-2) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $437,513Department: Helen DeVos Children’s Hospital Department of PsychologyAward Period: 9/15/2011 – 8/31/2014

NEUROSCIENCE RESEARCH

Epilepsy Principal Investigator: Elisevich, Kost, MDProject Title: Decision Support Systems for the Lateralization of Medial Temporal Lobe Epilepsy (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $58,935Department: Department of NeurosciencesAward Period: 9/1/2012 – 8/31/2015

Pediatric NeurologyPrincipal Investigator: DeRoos, Steven, MDProject Title: Feasibility Clinical Trial Evaluating a Personalized Medicine Approach for Patients with Tuberous Sclerosis ComplexSponsor: Van Andel Research InstituteAward Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of NeurologyAward Period: 5/1/2013 – 4/30/2016

Pediatric PsychologyPrincipal Investigator: Pastyrnak, Steven, PhDProject Title: Neonatal Neurobehavior and Outcomes in Very Preterm Infants (NOVI) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $70,690Department: Helen DeVos Children’s Hospital Department of PsychologyAward Period: 9/3/2013 – 8/31/2015

PULMONARY RESEARCHPrincipal Investigator: Girgis, Reda, MDProject Title: Long-Term Oxygen Treatment Trial (LOTT) (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: $43,599Department: Pulmonary Department Award Period: 3/6/2014 – 12/31/2014

Principal Investigator: Wilt, Jeffrey, MDProject Title: National Biological Sample and Data Repository for Pulmonary Arterial Hypertension (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Pulmonary Department Award Period: 3/3/2012 – 2/28/2015

PEDIATRIC DIABETES/ENDOCRINE RESEARCHPrincipal Investigator: Cemeroglu, Ayse, MDProject Title: TrialNet Natural History Study of the Development of Type 1 Diabetes (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Endocrine DiabetesAward Period: 4/27/2010 – 5/31/2015

Principal Investigator: Cemeroglu, Ayse, MDProject Title: Metformin Therapy for Overweight Adolescents With T1D: A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes (Subcontract)Sponsor: JAEB Center for Health Research Foundation (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Endocrine DiabetesAward Period: 3/1/2012 – 6/30/2015

PEDIATRIC NEPHROLOGY RESEARCHPrincipal Investigator: Cai, Yi, MDProject Title: Validation of PROMIS Pediatric Banks With Incident Nephrotic Syndrome (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric NephrologyAward Period: 6/1/2010 – 7/31/2014

Principal Investigator: Cai, Yi, MDProject Title: CureGN: Cure Glomerulonephropathy (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric NephrologyAward Period: 6/1/2014 – 5/31/2015

24

Principal Investigator: Cai, Yi, MDProject Title: CKiD: Chronic Kidney Disease in Children (Subcontract)Sponsor: National Institutes of Health (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric NephrologyAward Period: 2/1/2010 – 7/31/2015

PEDIATRIC PULMONOLOGY RESEARCHPrincipal Investigator: Millard, Susan, MDProject Title: Baby Observational and Nutritional Study (BONUS) (Subcontract)Sponsor: Cystic Fibrosis Foundation (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric PulmonologyAward Period: 2/1/2011 – 4/30/2016

Principal Investigator: Millard, Susan, MDProject Title: G551D Observational Study (GOAL) (Subcontract)Sponsor: Cystic Fibrosis Foundation Therapeutics (Subaward)Award Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric PulmonologyAward Period: 2/6/2012 – 12/31/2020

Principal Investigator: Millard, Susan, MDProject Title: The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF (EPIC-002)Sponsor: Cystic Fibrosis Foundation TherapeuticsAward Total: N/A (Per-Patient Reimbursement)Department: Helen DeVos Children’s Hospital Department of Pediatric PulmonologyAward Period: 9/1/2013 – 8/31/2018

PEDIATRIC UROLOGY RESEARCHPrincipal Investigator: Meldrum, Kirstan, MDProject Title: IL-18 Mediates Obstruction-Induced Renal Injury via TLR4 SignalingSponsor: National Institutes of HealthAward Total: $578,076Department: Helen DeVos Children’s Hospital Department of Pediatric UrologyAward Period: 4/1/2010 – 3/31/2016

PublicationsThe Research Department received the following publications for inclusion in the fiscal year 2014 Annual Report. The names of Spectrum Health researchers are boldface in each listing.

CANCER RESEARCH

Adult Brain Tumor

PublicationsThomas SL, Schultz CR, Mouzon E, Golembieski WA, El Naili R, Radakrishnan A, Lemke N, Poisson LM, Gutiérrez JA, Cottingham S, Rempel SA. Loss of Sparc in p53-null astrocytes promotes macrophage activation and phagocytosis resulting in decreased tumor size and tumor cell survival. Brain Pathol. 2014 May 26. doi: 10.1111/bpa.12161. [Epub ahead of print]. PMID: 24862407 [PubMed—as supplied by publisher].

Adult and Pediatric BMT

PublicationsAl-Homsi AS, Lai Z, Roy TS, Kouttab N. Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IkB and NFkB. Transpl Immunol. 2013 Dec: 29(1-4):1-6. doi: 10.1016/j.trim.2013.09.011. Epub 2013 Oct 5. PMID: 24103732.

Al-Homsi AS, Lai Z, Roy TS, Al-Malki MM, Kouttab N, Junghans RP. Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IkappaB and NF kapaB. Transpl Immunol. 2014 Jan: (40-45). doi: 10.1016/j.trim.2013.11.003.

Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, Winer E, Olszewski AJ, Al-Homsi AS, Kouttab N, Dubielecka PM. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia. 2014 Nov: 28(11):2165-77. doi: 10.1038/leu.2014.120. Epub 2014 Apr 4.

Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Hematol. 2014 Jun:165(6):793-800. doi: 10.1111/bjh.12824. Epub 2014 Mar 15. PMID: 24628515 [PubMed—indexed for MEDLINE].

25

PublicationsAdult and Pediatric Neurofibromatosis Type I (NFI)/Bone

PublicationsPelle DW, Ringler JW, Peacock JD, Kampfschulte K, Scholten DJ 2nd, Davis MM, Mitchell DS, Steensma MR. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res. 2014 Aug:164(2):139-48. doi: 10.1016/j.trsl.2014.03.005. Epub 2014 Mar 21. PMID: 24726460 [PubMed—indexed for MEDLINE].

Wolters PL, Martin S, Merker VL, Gardner KL, Hingtgen CM, Tonsgard JH, Schorry EK, Baldwin A; REiNS International Collaboration. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013 Nov 19:81(21 Suppl 1):S6-14. doi: 10.1212/01.wnl.0000435747.02780.bf. PMID: 24249806 [PubMed—indexed for MEDLINE]. PMCID: PMC3908341.

Adult and Pediatric Urologic Oncology

PublicationsBoelkins B, Kohnoski RM, Whelan CM, Bolthouse JT, Lane BR. The use of PCA3 can reduce the number of prostate biopsies performed in a community-based urology practice. Open J Urol. 2013 Sep; 3(5):200-205.

Coburn M, Amling C, Bahnson RR, Dahm P, Kerfoot BP, King L, Lane B, Ritchey ML, Scales Jr CD, Sundaram CP, Swing SR. Urology milestones. J Grad Med Educ. 2013:5(1 Suppl 1):79-98.

Demirjian S, Lane BR, Derweesh I, Takagi T, Fergany A, Campbell SC. Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. J Urol. 2013: In press. [Epub ahead of print].

Goldfarb R, Aderjoro O, Lane B, Kim SP, Weight C. Re: Positive surgical margins in robot-assisted partial nephrectomy: A multi-institutional analysis of oncologic outcomes (leave no tumor behind). J. Urol. 2014:190:1674-1679. In press. [Epub ahead of print].

Hobbs DJ, Zhou M, Campbell SC, Aydin H, Weight CJ, Lane BR. The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study. World J Urol. 2013 Oct; 31(5):1159-64. doi: 10.1007/s00345-012-0868-3. Epub 2012 Apr 15. PMID: 22527673 [PubMed—indexed for MEDLINE].

Lane BR, Campbell SC, Demirjian S, Fergany AF. Surgically induced chronic kidney disease may be associated with lower risk of progression and mortality than medical chronic kidney disease. J Urol. 2013: 189(5):1649-55.

Lane BR, Campbell SC, Gill IS. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol. 2013:190(1):44-9.

Lane BR, Golan S, Eggener S, Tobert CM, Kahnoski RJ, Kuitikov A, Smaldone M, Whelan CM, Shalhav A, Uzzo RG. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013:189(6):2047-53.

Mendonca SJ, Berenji M, Tobert CM, Stetler H, Bisel D, Lane BR. Evaluation of methods for dissemination of prostate cancer survivorship guidelines: a survey of primary care providers. Open J Urol. 2013:3(3):165-172.

Tobert CM, Boelkins B, Culver S, Mammen L, Kahnoski RJ, Lane BR. Surgeon assessment of renal preservation with partial nephrectomy provides information comparable to measurement of volume preservation with 3-dimensional image analysis. J Urol. 2014 May;191(5):1218-24. doi: 10.1016/j.juro.2013.11.003. Epub 2013 Nov 7. PMID: 24211601.

Tobert CM, Riedinger CB, Lane BR. Do we know (or just believe) that partial nephrectomy leads to better survival than radical nephrectomy for renal cancer? World J Urol. 2014:32(3):573-579.

Tobert CM, Uzzo RG, Wood CG, Lane BR. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the society of urologic oncology. Urol Oncol. 2013:31(7):1316-1320.

Book Chapters/Reviews/EssaysLane BR, Demirjian S, Derweesh IH, Riedinger CB, Fergany AF, Campbell SC. Is all chronic kidney disease created equal? Curr Opin Urol. 2014:24(2): 127.

Lane BR. Molecular markers of kidney injury. Urol Oncol Sem Invest. 2013:31:682-5.

Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM. The management of a clinical T1b renal tumor in the presence of a normal contralateral kidney: radical nephrectomy. J Urol. 2013:189(4):1198-202.

AwardsLane, BR. (March/April 2014). Special Recognition. Women of Achievement & Courage in Healthcare. Michigan Women’s Foundation. Grand Rapids, MI.

Adult Surgical Oncology

PublicationsMitchell EJ, Siripong A, Chung MH. Is a routine colonoscopy before esophagectomy necessary? Am Surg. 2014 May:80(5):515-7. PMID: 24887735 [PubMed—indexed for MEDLINE].

26

Wright GP, Foster SM, Chung MH. Esophagectomy in patients with prior percutaneous endoscopic gastrostomy tube placement. Am J Surg. 2014 Mar:207(3):361-5; discussion 364-5. doi: 10.1016/j.amjsurg.2013.10.012. Epub 2013 Dec 19. PMID: 24418181 [PubMed—indexed for MEDLINE].

Wright GP, Mitchell EJ, McClure AM, Onesti JK, Moyo SC, Brown AR, Peshkepija A, Scott GL, Chung MH. Comparison of stapling techniques and management of the mesoappendix in laparoscopic appendectomy. Surg Laparosc Endosc Percutan Tech. 2014 Apr 19. [Epub ahead of print]. PMID: 24752160 [PubMed—as supplied by publisher].

Wright GP, Morrow JB, Shaheen M, Goslin BJ, Baatenburg L, Chung MH. Accuracy of endoscopic ultrasound in the evaluation of cystic pancreatic neoplasms: a community hospital experience. Pancreas. 2014 Apr:43(3):465-9. doi: 0.1097/MPA.0000000000000057. PMID: 24622081 [PubMed—indexed for MEDLINE].

Wright GP, Siripong A, Winton MD, Mitchell EJ, Goslin BJ, Chung MH. Selective laparoscopic approach in suspected gallbladder malignancy. JSLS. 2013 Oct-Dec:17(4):596-601. doi: 10.4293/108680813X13693422519352. PMID: 24398202 [PubMed—indexed for MEDLINE]. PMCID: PMC3866064.

Wright GP, Wolf AM, Ambrosi G, Dull MB, Chung MH. Patient perspectives on postoperative visits after common general operative procedures. Surgery. 2013 Oct:154(4):934-9; discussion 939-40. doi: 10.1016/j.surg.2013.05.005. Epub 2013 Sep 3.PMID: 24008090 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/EssaysOnesti JK, Chung MH, Jain DH, Stafford MM, Attawala PP. A review of splenic pathology in distal pancreatectomies. Pancreatology. 2013 Nov-Dec:13(6):625-8. doi: 10.1016/j.pan.2013.10.006. Epub 2013 Oct 23. PMID: 24280581 [PubMed—indexed for MEDLINE].

Adult Uterine and Ovarian Cancer

PublicationsBillmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol. 2014 Feb 10; 32(5):465-70. doi: 10.1200/JCO.2013.51.1006. Epub 2014 Jan 6. PMID: 24395845 [PubMed—indexed for MEDLINE].

Colorectal Cancer

PublicationsAsgeirsson T, Jrebi N, Feo L, Kerwel T, Luchtefeld M, Senagore AJ. Incremental cost of complications in colectomy: a warranty guided approach to surgical quality improvement. Am J Surg. 2014 Mar:207(3):422-6; discussion 425-6. doi: 10.1016/j.amjsurg.2013.11.002. Epub 2013 Dec 27. PMID: 24581768 [PubMed—indexed for MEDLINE].

Senagore A, Lane FR, Lee E, Wexner S, Dujovny N, Sklow B, Rider P, Bonello J; Bioabsorbable Staple Line Reinforcement Study Group. Bioabsorbable staple line reinforcement in restorative proctectomy and anterior resection: a randomized study. Dis Colon Rectum. 2014 Mar:57(3):324-30. doi: 10.1097/DCR.0000000000000065. PMID: 24509454 [PubMed—indexed for MEDLINE].

Shantha Kumara HM, Myers EA, Herath SA, Njoh L, Yan X, Kirchoff D, Dujovny N, Whelan RL. Minimally invasive colorectal resection for benign pathology is associated with persistent proangiogenic plasma compositional changes. Dis Colon Rectum. 2014 Jun:57(6):740-6. doi: 10.1097/DCR.0000000000000062. PMID: 24807599 [PubMed—indexed for MEDLINE].

Lung

PublicationsHoffman AJ, Brintnall RA, Brown JK, von Eye A, Jones LW, Alderink G, Ritz-Holland D, Enter M, Patzelt LH, VanOtteren GM. Virtual reality bringing a new reality to postthoracotomy lung cancer patients via a home-based exercise intervention targeting fatigue while undergoing adjuvant treatment. Cancer Nurs. 2014 Jan-Feb:37(1):23-33. doi: 10.1097/NCC.0b013e318278d52f. PMID: 23348662 [PubMed—in process].

Hoffman AJ, Brintnall RA, von Eye A, Jones LW, Alderink G, Patzelt LH, Brown JK. A rehabilitation program for lung cancer patients during postthoracotomy chemotherapy. Onco Targets Ther. 2014 Mar 10:7:415-23. doi: 10.2147/OTT.S57262. eCollection 2014. PMID: 24648745 [PubMed] PMCID: PMC3956688.

Imaging

PublicationsChanda N, Upendran A, Boote EJ, Zambre A, Axiak S, Selting K, Katti KV, Leevy WM, Afrasiabi Z, Vimal J, Singh J, Lattimer JC, Kannan R. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nano-platform for computer tomography theranostics. J Biomed Nanotechnol. 2014 Mar:10(3):383-92. PMID: 24730234 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/Essays Boote E. Phantoms for Ultrasound Experimentation and Quality Control. (In: L. DeWerd, M. Kissick, Editors). The Phantoms of Medical and Health Physics. New York: Springer. 2014. Pages 159-179.

Pediatric Radiology

Book Chapters/Reviews/EssaysFaasse T. Positron emission tomography-computed tomography data acquisition and image management. (In: S. Misciagna, Editor). Positron Emission Tomography—Recent Developments in Instrumentation, Research and Clinical Oncological Practice. InTech. 2013. Pages 277-282.

Shreve P, Faasse T. Role of positron emission tomography-computed tomography in pulmonary neoplasms. Radiol Clin North Am. 2013 Sep: 51(5):767-79. doi: 10.1016/j.rcl.2013.05.001. Epub 2013 Jul 17. PMID: 24010905 [PubMed—indexed for MEDLINE].

27

CARDIOVASCULAR RESEARCH

Cardiovascular

PublicationsPontén A, Walsh S, Malan D, Xian X, Schéele S, Tarnawski L, Fleischmann BK, Jovinge S. FACS-based isolation, propagation and characterization of mouse embryonic cardiomyocytes based on VCAM-1 surface marker expression. PLoS One. 2013 Dec 30; 8(12):e82403. doi: 10.1371/journal.pone.0082403. eCollection 2013. PMID: 24386094 [PubMed—indexed for MEDLINE].

Cardiothoracic Surgery

PublicationsAboagye JK, Kaiser HE, Hayanga AJ. Rural-Urban Differences in Access to Specialist Providers of Colorectal Cancer Care in the United States: A Physician Workforce Issue. JAMA Surg. 2014 Apr 16. doi: 10.1001/jamasurg.2013.5062. [Epub ahead of print]. PMID: 24740165 [PubMed—as supplied by publisher].

Chan PG, Hayanga AJ, Badhwar V. Repair of rheumatic mitral stenosis with bicommissural release, anterior leaflet augmentation and oversized annuloplasty. Multimed Man Cardiothorac Surg. 2014 Jan; 2014:mmt020. doi: 10.1093/mmcts/mmt020. PMID: 24435097 [PubMed—in process].

Schaheen LW, Hayanga AJ, Badhwar V. Chordal relocation for repair of anterior mitral leaflet flail: a reproducible option. Multimed Man Cardiothorac Surg. 2014 Jan; 2014:mmt021. doi: 10.1093/mmcts/mmt021. PMID: 24435098 [PubMed—in process].

Electrophysiology

PublicationsAssaad MC, Calle-Muller C, Dahu M, Nowak RM, Hudson MP, Mueller C, Jacobsen G, McCord J. The relationship between chest pain duration and the incidence of acute myocardial infarction among patients with acute chest pain. Crit Pathw Cardiol. 2013 Sep; 12(3):150-3. doi: 10.1097/ HPC.0b013e31829274ff. PMID: 23892946 [PubMed—indexed for MEDLINE].

Banga S, Chalfoun N, Finta B, Elmouchi D, Dahu M, Woelfel A, McNamara RF, Fritz T, Schuitema JI, Judson CA, Gauri A. Syncope and recurrent ventricular tachycardia with a newly identified desmosomal gene mutation. Glob Cardiol Sci Pract. 2013 Nov 1; 2013(3):261-8. doi: 10.5339/gcsp.2013.33. eCollection 2013. PMID: 24689027 [PubMed]. PMCID: PMC3963755.

Elmouchi DA, Rosema S, Vanoosterhout SM, Khan M, Davis AT, Gauri AJ, Finta B, Woelfel AK, Chalfoun NT. Cardiac perforation and lead dislodgement after implantation of a MR-conditional pacing lead: a single-center experience. Pacing Clin Electrophysiol. 2014 Jan; 37(1):4-10. doi: 10.1111/pace.12293. Epub 2013 Nov 11. PMID: 24215291 [PubMed—indexed for MEDLINE].

Elmouchi DA, Chalfoun N, Gauri A. Attitudes of Implanting Physicians About Cardiac Rhythm Management Devices and Their Features. ISRN Cardiol. 2013 Dec 26; 2013:247586. doi: 10.1155/2013/247586. eCollection 2013. PMID: 24490084 [PubMed]. PMCID: PMC388869.

Khan M, Gauri A, Grifka R, Elmouchi D. Radiofrequency Ablation of a Left Atrial Appendage Tachycardia on ECMO Support. Case Rep Pediatr. 2013; 2013:203241. doi: 10.1155/2013/203241. Epub 2013 Nov 28. PMID: 24369520 [PubMed]. PMCID: PMC3863555.

Book Chapters/Reviews/EssaysElmouchi D. Response: Diagnostic criteria for acute pericarditis need closer attention. Pacing Clin Electrophysiol. 2014 May; 37(5):658-9. doi: 10.1111/pace.12382. Epub 2014 Mar 20. PMID: 24645895 [PubMed—indexed for MEDLINE].

Heart Failure

PublicationsWhellan DJ, Goodlin SJ, Dickinson MG, Heidenreich PA, Jaenicke C, Stough WG, Rich MW; Quality of Care Committee, Heart Failure Society of America. End-of-life care in patients with heart failure. J Card Fail. 2014 Feb; 20(2):121-34. doi: 10.1016/j.cardfail.2013.12.003. PMID: 24556532 [PubMed—indexed for MEDLINE].

Interventional Cardiology

PublicationsAdams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014 May 8; 370(19):1790-8. doi: 10.1056/NEJMoa1400590. Epub 2014 Mar 29. PMID: 24678937 [PubMed—indexed for MEDLINE].

Elmouchi DA, VanOosterhout S, Muthusamy P, Khan M, Puetz C, Davis AT, Brown MD. Impact of an emergency department-initiated clinical protocol for the evaluation and treatment of atrial fibrillation. Crit Pathw Cardiol. 2014 Jun;13(2):43-8. doi: 10.1097/HPC. 0000000000000008. PMID: 24827879 [PubMed—indexed for MEDLINE].

Kooiman J, Seth M, Dixon S, Wohns D, LaLonde T, Rao SV, Gurm HS. Risk of acute kidney injury after percutaneous coronary interventions using radial versus femoral vascular access: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Interv. 2014 Apr; 7(2):190-8. doi: 10.1161/CIRCINTERVENTIONS.113.000778. Epub 2014 Feb 25. PMID: 24569598 [PubMed—in process].

Kooiman J, Seth M, Dixon S, Wohns D, LaLonde T, Rao SV, Gurm HS. Response to letters regarding article, “Risk of acute kidney injury after percutaneous coronary interventions using radial versus femoral vascular access: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.” Circ Cardiovasc Interv. 2014 Jun; 7(3):421. doi: 10.1161/CIRCINTERVENTIONS.114.001590. PMID: 24944310 [PubMed—in process].

Madder RD, Wohns DH, Muller JE. Detection by intracoronary near-infrared spectroscopy of lipid core plaque at culprit sites in survivors of cardiac arrest. J Invasive Cardiol. 2014 Feb; 26(2):78-9. PMID: 24486666 [PubMed—indexed for MEDLINE].

28

Wohns D, Muthusamy P, Davis AT, Khan M, Postma JK, Williams EE, Gile CM, Scotti DJ, Gregory D. Economic and operational implications of a standardized approach to hemodynamic support therapy using percutaneous cardiac assist devices. Innovations (Phila). 2014 Jan-Feb; 9(1):38-42. doi: 10.1097/IMI.0000000000000047 PMID: 24562292 [PubMed—indexed for MEDLINE].

Pediatric Congenital Heart Disease

PublicationsBlack DE, Bryant J, Peebles C, Godfrey KM, Hanson M, Vettukattil J. Tissue motion annular displacement of the mitral valve using two-dimensional speckle tracking echocardiography predicts the left ventricular ejection fraction in normal children. Cardiol Young. 2014 Aug; 24(4):640-8. doi: 10.1017/S1047951113000863. Epub 2013 Jun 27. PMID: 23803408 [PubMed—in process].

Black D, Bryant J, Peebles C, Davies L, Inskip H, Godfrey K, Vettukattil J, Hanson M. Increased regional deformation of the left ventricle in normal children with increased body mass index: implications for future cardiovascular health. Pediatr Cardiol. 2014 Feb; 35(2):315-22.

Black D, Vettukattil J. Advanced echocardiographic imaging of the congenitally malformed heart. Curr Cardiol Rev. 2013 Aug; 9(3):241-52. PMID: 23228075 [PubMed—indexed for MEDLINE] PMCID: PMC3780349.

Fitzsimmons SJ, Macdonald S, Ritchens T, Vettukattil J. Transcatheter closure of an inferior post infarction VSD using a customised device. Eu Heart J 2013 Aug 1; 34(suppl 1).

Book Chapters/Reviews/EssaysBlack D, Vettukattil J. Tricuspid valve dysplasia: from fetus to adult. (In: A. Giamberti, M. Chessa, Editors). The Tricuspid Valve in Congenital Heart Disease. Verlag Italia: Springer Milan. 2014. Pages 13-23.

Vettukattil J. Transesophageal 2D and 3D Echocardiographic Guidance. (In: H. Sievert, S.A. Qureshi, N. Wilson, ZM Hijazi, Editors). Interventions in Structural, Valvular and Congenital Heart Disease. Boca Raton, FL: CRC Press. 2014. Pages 59-66.

PatentsVettukattil, J.—Atrial Flow Regulator—Pending.

Vascular Surgery

PublicationsCuff R, Banegas S, Mansour A, Chambers C, Wong P, Slaikeu J. Endovascular repair of bilateral common iliac artery aneurysms following open abdominal aortic aneurysm repair with preservation of both hypogastric arteries using commercially available stent grafts. J Vasc Surg. 2014 Feb; 59(2):516-9. doi: 10.1016/j.jvs.2013.03.005. Epub 2013 May 1. PMID: 23642920 [PubMed—indexed for MEDLINE].

Jackson EA, Munir K, Schreiber T, Rubin JR, Cuff R, Gallagher KA, Henke PK, Gurm HS, Grossman PM. Impact of sex on morbidity and mortality rates after lower extremity interventions for peripheral arterial disease: observations from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Am Coll Cardiol. 2014 Jun 17; 63(23):2525-30. doi: 10.1016/j.jacc.2014.03.036. Epub 2014 Apr 23. PMID: 24747101 [PubMed—indexed for MEDLINE].

Liao TH, Watson JJ, Mansour MA, Cuff RF, Banegas SL, Chambers CM, Slaikeu JD, Wong PY. Preliminary results of zenith fenestrated abdominal aortic aneurysm endovascular grafts. Am J Surg. 2014 Mar; 207(3):417-21; discussion 421. doi:10.1016/j.amjsurg.2013.09.015. Epub 2013 Dec 21. PMID: 24581767 [PubMed—indexed for MEDLINE].

CRITICAL CARE RESEARCH

Critical Care

PublicationsChopra V, Govindan S, Sweis R, Teply M, Kuo S, Barron J, Thompson R, Saint S. Do physicians know which of their patients have central venous catheters? A multi-center, cross-sectional study [abstract]. J Hosp Med. 2014 Mar:9 Suppl 2:77.

Lewandowski-Belfer JJ, Patel AV, Darracott RM, Jackson DA, Nordeen JD, Freeman WD. Safety and efficacy of repeated doses of 14.6 or 23.4% hypertonic saline for refractory intracranial hypertension. Neurocrit Care. 2014 Jun:20(3):436-42. doi: 10.1007/s12028-013-9907-1. PMID: 24026522.

Book Chapters/Reviews/EssaysWatson N. Valvular Disorders. (In: SM Berg and EA Bittner, Editors). The Massachusetts General Hospital Review of Critical Care Medicine. (1st Edition). Philadelphia, PA: Lippincott Williams & Wilkins. 2013. Pages 14-20.

Pediatric Critical Care

PublicationsBeauchamp H, Hassan N, Ndika A, Zuiderveen S, Olivero A, Davis A, Hackbarth R, Rajasekaran S, et al. Transfusion as an independent predictor of severity in critically ill children. Crit Care Med. 2013. doi: 10.1097/01.ccm.0000439829.89627.30.

Michiels E, Dumas F, Quan L, Selby L, Copass M, Rea T. Long-term outcomes following pediatric out-of-hospital cardiac arrest.* Pediatr Crit Care Med. 2013 Oct:14(8):755-60. doi: 10.1097/PCC.0b013e31829763e2. [Pediatr Crit Care Med. 2013] PMID: 23925145 [PubMed—indexed for MEDLINE]. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, Zuiderveen S, Birmingham J. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children.* Pediatr Crit Care Med. 2014 Jun:15(5):401-8. doi: 10.1097/PCC.0000000000000078. PMID: 24583503.

EMERGENCY MEDICINE RESEARCH

PublicationsBortsov AV, Platts-Mills TF, Peak DA, Jones JS, Swor RA, Domeier RM, Lee DC, Rathlev NK, Hendry PL, Fillingim RB, McLean SA. Pain distribution and predictors of widespread pain in the immediate aftermath of motor vehicle collision. Eur J Pain. 2013 Sep:17(8):1243-51. doi: 10.1002/j.1532-2149.2013.00285.x. Epub 2013 Jan 20. PMID: 23335385 [PubMed—indexed for MEDLINE]. PMCID: PMC3644322.

29

Bortsov AV, Smith JE, Diatchenko L, Soward AC, Ulirsch JC, Rossi C, Swor RA, Hauda WE, Peak DA, Jones JS, Holbrook D, Rathlev NK, Foley KA, Lee DC, Collette R, Domeier RM, Hendry PL, McLean SA. Polymorphisms in the glucocorticoid receptor co-chaperone FKBP5 predict persistent musculoskeletal pain after traumatic stress exposure. Pain. 2013 Aug: 154(8):1419-26. doi: 10.1016/j.pain.2013.04.037. Epub 2013 Apr 26. PMID: 23707272 [PubMed—indexed for MEDLINE]. PMCID: PMC3699900.

McLean SA, Ulirsch JC, Slade GD, Soward AC, Swor RA, Peak DA, Jones JS, Rathlev NK, Lee DC, Domeier RM, Hendry PL, Bortsov AV, Bair E. Incidence and predictors of neck and widespread pain after motor vehicle collision among U.S. litigants and nonlitigants. Pain. 2014 Feb:155(2):309-21. doi:10.1016/j.pain.2013.10.016. Epub 2013 Oct 18. PMID: 24145211 [PubMed—indexed for MEDLINE]. PMCID: PMC3902045 [Available on 2015/2/1].

Reynolds JC, Abraham MK, Barrueto FF Jr, Lemkin DL, Hirshon JM. Propofol for procedural sedation and analgesia reduced dedicated emergency nursing time while maintaining safety in a community emergency department. J Emerg Nurs. 2013 Sep: 39(5):502-7. doi: 10.1016/j.jen.2013.03.001. Epub 2013 May 6. PMID: 23657007 [PubMed—indexed for MEDLINE].

Reynolds JC, Frisch A, Rittenberger JC, Callaway CW. Duration of resuscitation efforts and functional outcome after out-of-hospital cardiac arrest: when should we change to novel therapies? Circulation. 2013 Dec 3:128(23):2488-94. doi: 10.1161/CIRCULATIONAHA. 113.002408. Epub 2013 Nov 17. PMID: 24243885 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/EssaysIshiyama D, Jones J. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: Is nebulised naloxone effective in opioid overdose? Emerg Med J. 2013 Oct:30(10):860. doi: 10.1136/emermed-2013-203100.3. PMID:24014692 [PubMed—indexed for MEDLINE].

Queen B, Judge B, Jones J. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Excited delirium syndrome and sudden death. Emerg Med J. 2013 Nov:30(11):958-60. doi: 10.1136/emermed-2013-203139.1. PMID: 24142942 [PubMed—indexed for MEDLINE].

Queen B, Judge B, Jones J. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2: Clinical identification of acute thoracic aortic dissection. Emerg Med J. 2014 Feb: 31(2):170-1. doi: 10.1136/emermed-2013-203506.2. PMID: 24429252 [PubMed—indexed for MEDLINE].

GENERAL SURGERY RESEARCH

PublicationsChapman AJ, Titus R, Ferenchick H, Davis A, Rodriguez C. Repeal of the Michigan helmet law: early clinical impacts. Am J Surg. 2014 Mar:207(3):352-6; discussion 355-6. doi: 10.1016/j.amjsurg.2013.12.001. Epub 2013 Dec 25. PMID: 24581760 [PubMed—indexed for MEDLINE].

Wright GP, Davis AT, Koehler TJ, Melnik MK, Chung MH. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol. 2014 Oct: 21(11):3497-503. doi: 10.1245/s10434-014-3782-7. Epub 2014 May 17. PMID: 24838367 [PubMed—in process].

Wright GP, Foster SM, Chung MH. Esophagectomy in patients with prior percutaneous endoscopic gastrostomy tube placement. Am J Surg. 2014 Mar:207(3):361-5; discussion 364-5. doi:10.1016/j.amjsurg.2013.10.012. Epub 2013 Dec 19. PMID: 24418181 [PubMed—indexed for MEDLINE].

Wright GP, Koehler TJ, Davis AT, Chung MH. The drowning whipple: perioperative fluid balance and outcomes following pancreaticoduodenectomy. J Surg Oncol. 2014 Sep:110(4):407-11. doi: 10.1002/jso.23662. Epub 2014 May 26. PMID: 24861716 [PubMed—indexed for MEDLINE].

Wright GP, Mitchell EJ, McClure AM, Onesti JK, Moyo SC, Brown AR, Peshkepija A, Scott GL, Chung MH. Comparison of Stapling Techniques and Management of the Mesoappendix in Laparoscopic Appendectomy. Surg Laparosc Endosc Percutan Tech. 2014 Apr 19. [Epub ahead of print]. PMID: 24752160 [PubMed—as supplied by publisher].

Wright GP, Morrow JB, Shaheen M, Goslin BJ, Baatenburg L, Chung MH. Accuracy of endoscopic ultrasound in the evaluation of cystic pancreatic neoplasms: a community hospital experience. Pancreas. 2014 Apr:43(3):465-9. doi:10.1097/MPA.0000000000000057. PMID: 24622081 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/EssaysWright, GP. Consequences [Essay]. Bulletin of the American College of Surgeons, 2014 Jan.

NEONATAL RESEARCH

PublicationsMeghea CI, Raffo JE, VanderMeulen P, Roman LA. Moving toward evidence-based federal Healthy Start program evaluations: accounting for bias in birth outcomes studies. Am J Public Health. 2014 Feb:104 Suppl 1:S25-7. doi: 10.2105/AJPH.2013.301276. Epub 2013 Dec 19. PMID: 24354826 [PubMed—indexed for MEDLINE].

Phadke A, Msall ME, Droste P, Allred EN, O’Shea TM, Kuban K, Dammann O, Leviton A; ELGAN Study Investigators. Impaired visual fixation at the age of 2 years in children born before the twenty-eighth week of gestation. Antecedents and correlates in the multicenter ELGAN study. Pediatr Neurol. 2014 Jul:51(1):36-42. doi: 10.1016/j.pediatrneurol. 2014.03.007. Epub 2014 Mar 15. PMID: 24938138 [PubMed—in process]. PMCID: PMC4062923 [Available on 2015/7/1].

Schafer D, Boogaart S, Johnson L, Keezel C, Ruperts L, Vander Laan KJ. Comparison of neonatal skin sensor temperatures with axillary temperature: does skin sensor placement really matter? Adv Neonatal Care. 2014 Feb:14(1):52-60. doi: 10.1097/ANC.0000000000000027. PMID: 24472889 [PubMed—indexed for MEDLINE].

30

NEUROSCIENCE RESEARCH

Adult Stroke and Traumatic Brain Injury

PublicationsOostema JA, Delano M, Bhatt A, Brown MD. Incorporating diffusion-weighted magnetic resonance imaging into an observation unit transient ischemic attack pathway: a prospective study. Neurohospitalist. 2014 Apr:4(2):66-73. doi: 10.1177/1941874413519804. PMID: 24707334 [PubMed]. PMCID: PMC3975796.

Epilepsy

PublicationsPatra S, Elisevich K, Podell K, Schultz L, Gaddam S, Smith B, Spanaki-Varelas M. Influence of age and location of ictal onset on postoperative outcome in patients with localization-related epilepsy. Br J Neurosurg. 2014 Jan:28(1):61-7. doi: 10.3109/02688697.2013.817529. Epub 2013 Jul 25. PMID: 23885724 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/EssaysSmith BJ. Closing the Major Gap in PNES Research: Finding a Home for a Borderland Disorder. Epilepsy Curr. 2014 Mar:14(2):63-7. doi: 10.5698/1535-7597-14.2.63. PMID: 24872779 [PubMed] PMCID: PMC4010877.

ORTHOPAEDICS/SPORTS MEDICINE RESEARCH

PublicationsButler PD, Mellecker CJ, Rudert MJ, Albright JP. Single-bundle versus double-bundle ACL reconstructions in isolation and in conjunction with extra-articular iliotibial band tenodesis. Iowa Orthop J. 2013:33:97-106. PMID: 24027468 [PubMed—indexed for MEDLINE]. PMCID: PMC3748900.

Herzog MA, Oliver SM, Ringler JR, Jones CB, Sietsema DL. Reply to the Letter to the Editor: Mid-America Orthopaedic Association Physician in Training Award: Surgical technique: Pediatric supracondylar humerus fractures: a technique to aid closed reduction. Clin Orthop Relat Res. 2014 Jan:472(1):381-2. doi: 10.1007/s11999-013-3355-2. Epub 2013 Oct 25. PMID: 24158543 [PubMed—indexed for MEDLINE]. PMCID: PMC3889407.

Hoffmann MF, Burgers TA, Mason JJ, Williams BO, Sietsema DL, Jones CB. Biomechanical evaluation of fracture fixation constructs using a variable-angle locked periprosthetic femur plate system. Injury. 2014 Jul:45(7):1035-41. doi:10.1016/j.injury.2014.02.038. Epub 2014 Mar 11. PMID: 24680467 [PubMed—in process].

Hoffmann MF, Jones CB, Sietsema DL. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report. Spine J. 2013 Oct:13(10):1244-52. doi:10.1016/j.spinee.2013.06.022. Epub 2013 Aug 22. PMID: 23973099 [PubMed—indexed for MEDLINE].

Book Chapters/Reviews/EssaysCarson JD, Lawrence DW, Kraft SA, Garel A, Snow CL, Chatterjee A, Libfeld P, MacKenzie HM, Thornton JS, Moineddin R, Frémont P. Premature return to play and return to learn after a sport-related concussion: physician’s chart review. Can Fam Physician. 2014 Jun:60(6):e310, e312-5. PMID: 24925965 [PubMed—in process]. PMCID: PMC4055342.

PEDIATRIC DIABETES/ENDOCRINE RESEARCH

PublicationsCemeroglu AP, Can A, Davis AT, Kleis L, Daniel MS, Rapp SM, Koehler TJ. Comparison of the expectations of caregivers and children with type 1 diabetes mellitus for independence in diabetes care-related tasks. Endocr Pract. 2014 Jul:20(7):629-37. doi: 10.4158/EP13472.OR. PMID: 24449680 [PubMed—in process]. Cemeroglu AP, Kleis L, Wood A, Parkes C, Wood MA, Davis AT. Comparison of the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Postprandial Blood Glucose Levels in Children with Type 1 DM on Multiple Daily Injections. Endocr Pract. 2013 Jul-Aug:19(4):614-619.

Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, Peters AL, Bode BW, Aleppo G, Hirsch IB, Kleis L, Chase HP, DuBose SN, Miller KM, Beck RW, Adi S; T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014 Oct:37(10):2702-9. doi: 10.2337/dc14-0303. Epub 2014 Jul 10. PMID: 25011947 [PubMed—in process].

PHARMACY RESEARCH

PublicationsMichaud CJ, Thomas WL, McAllen KJ. Early pharmacological treatment of delirium may reduce physical restraint use: a retrospective study. Ann Pharmacother. 2014 Mar:48(3):328-34. doi: 10.1177/1060028013513559. Epub 2013 Nov 18. PMID: 24259659 [PubMed—indexed for MEDLINE].

WOMEN’S HEALTH RESEARCH

Obstetrics and Gynecology

PublicationsBarber E, Schink J, Lurain J. Hepatic metastasis in gestational trophoblastic neoplasia: patient characteristics, prognostic factors, and outcomes. J Reprod Med. 2014 May:59(5-6): 199-203.Barber E, Zsiros E, Lurain J, Rademaker A, Schink J, Neubauer N. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol. 2013 Jul:24(3):258-64.

31

Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014 Feb 1:120(3):344-51. doi: 10.1002/cncr.28421. Epub 2013 Oct 24. PMID: 24166194 [PubMed—indexed for MEDLINE]. PMCID: PMC4250045 [Available on 2015/2/1].

De Oliveria GS Jr, McCarthy R, Turan A, Schink J, Fitzgerald PC, Sessler DI. Is Dexamethasone Associated With Recurrence of Ovarian Cancer? Anesth Analg. 2014 Jun:118(8): 1213-8. doi: 10.1213/ANE. 0b013e3182a5d656.

Doll KM, Donnelly E, Helenowski I, Rosenbloom L, Small W Jr, Schink JC, Lurain JR. Radical hysterectomy compared with primary radiation for treatment of stage IB1 cervix cancer. Am J Clin Oncol. 2014 Feb:37(1):30-4. doi: 10.1097/COC.0b013e31826103d0. PMID: 22992622 [PubMed—indexed for MEDLINE].

Donnelly E, Refaat T, Gentile M, Herskovic A, Boyle J, Helenowski I, Rademaker A, Lurain J, Schink J, Singh D, Strauss J, Small W. Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone. Am J Clin Oncol. 2013 Jul.

Pavone M, Hirshfeld-Cytron J, Tingen C, Thomas J, Lowe MP, Schink J, Woodruff KT. Human Ovarian Tissue Cortex Surrounding Benign and Malignant Lesions. Reprod Sci. 2013 Oct 20. doi: 10.1177/1933719113506498.

Refaat T, Donnelly E, Gentile M, Novak C, Yuan Y, Khedr G, Helenowksi I, Lurain J, Schink J, Rademaker A, Sathiaseelan V, Strauss J, Small W. Low-Dose-Rate Brachytherapy Boosting Concurrent Chemo-radiation as a Definitive Treatment Modality for Cervical Cancer. Am J Clin Oncol. 2014:00:000-000. doi:10.1097/COC.0000000000000035.

Rutherford T, Orr Jr. J, Grendys Jr. E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013. doi:10.1016/j.ygyno.2013.08.009.

Simon MA, de la Riva EE, Bergan R, Norbeck C, McKoy JM, Kylesza P, Dong X, Schink J, Fleisher L. Improving Diversity in Cancer Research Trials: The Story of the Cancer Disparities Research Network. J Cancer Educ. 2014 Jun:29(2):366-74. doi:10.1007/s13187-014-0617-y.

Trosman J, Weldon C, Schink J, Gradishar W, Benson A. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer. J Comp Eff Res. 2013 Jul:2(4):461-77.

Book Chapters/Reviews/EssaysGebhart JB, Heisler CA. Vaginal Hysterectomy for Uterosacral Plication. (In: R.G. Rogers, V.W. Sung, C.B. Iglesia, R. Thaker, Editors). Female Pelvic Medicine and Reconstructive Surgery, Clinical Practice and Surgery Atlas (1st Edition). New York: McGraw-Hill Professional. 2013. Pages 487-500.

Kerkmeijer LGW, Schnik JC. How Should Early Gestational Trophoblastic Disease Be Managed? (In: J.A. Ledermann, C.L. Creutzberg, M.A. Quinn, Editors). Controversies in Gynecological Cancer. 2014. London: Springer Verlag. Pages 285-295.

Schink JC, Lurain JR. Gestational Trophoblastic Disease: Molar Pregnancy and Gestational Trophoblastic Neoplasia. (In: R.R. Barakat, A. Berchuck, M. Markman, M.E. Randall, Editors). Principles and Practice of Gynecologic Oncology. (6th Edition). 2013. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health. Pages 886-908.

32 X18082 FY15.13.1 © Spectrum Health 05.2015

Spectrum Health Research Office100 Michigan Street NE, MC038Grand Rapids, MI 49503616.391.3050spectrumhealth.org/research

Documents

Transforming Lives Through Research - Spectrum Health · 2016-10-24 · Transforming Lives Through Research Spectrum Health Research Report 2014. 2 Table of Contents Letter from the